Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Urigen Pharmaceuticals, a specialty pharmaceutical company, has secured $257,000 in financing from Platinum - Montaur Life Sciences. This increases Platinum's total investment in Urigen to $2.36 million.
Subscribe to our email newsletter
The proceeds from the financing will be used to provide the financial flexibility to advance partnering and M&A discussions for Urigen’s URG101 program for painful bladder syndrome and URG301 program for overactive bladder.
As part of this process, the company has engaged a strategic advisor who will work with management to identify and develop additional opportunities to strengthen Urigen’s competitive position and to advance its urological programs by identifying and assessing potential strategic partners and additional financing alternatives.
William Garner, CEO of Urigen Pharmaceuticals, said: “Securing this financing provides the resources we need to continue ongoing strategic discussions.”